Indications -- Psoriasis/Chronic Inflammation

Sponsor

Biotech / Medical: Indications -- Psoriasis/Chronic Inflammation

Posts: 617 | Member SubjectMarks: 51 | No Bans

Moderated By: scaram(o)uche -- (Moderated) -- Started: 2/18/2001 6:06:37 PM Revision History

Go to reply# or date (mm/dd/yy):

Reply	Message Preview	From	Recs	Date
617	"Genomic responses in mouse models poorly mimic human inflammatory diseases	tuck	-	02/13/2013 11:47 AM
616	ALLSCHWIL/BASEL, SWITZERLAND - 18 December 2012 - Actelion (SIX: ATLN) announced	nigel bates	-	12/18/2012 08:13 AM
615	NDIANAPOLIS, Dec. 13, 2012 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) ann	nigel bates	-	12/14/2012 06:41 AM
614	Free Radic Biol Med. 2012 Nov 1;54C:1-16. doi: 10.1016/j.freeradbiomed.2012.10.5	scaram(o)uche	-	12/04/2012 04:22 PM
613	PLoS One. 2012;7(11):e49547. doi: 10.1371/journal.pone.0049547. Epub 2012 Nov 14	scaram(o)uche	-	11/21/2012 11:56 AM
612	PLoS One. 2012;7(9):e44547. Epub 2012 Sep 6. SU5416, a VEGF Receptor Inhibitor	scaram(o)uche	-	10/13/2012 08:53 PM
611	re. IL-17... secukinumab (AIN457, Novartis) is going to phase III for psoria	scaram(o)uche	-	10/05/2012 01:53 PM
610	Cellceutix Informed by FDA That 505(b)(2) Application Would Be an Acceptable A	Savant	-	06/14/2012 01:36 AM
609	One of biotech's first therapeutic projects, the magic CD4 epitope that tole	scaram(o)uche	-	08/20/2011 02:33 PM
608	>>The evolution of drug resistance and the curious orthodoxy of aggressive	tuck	-	06/28/2011 10:54 AM
607	ABBOTT PARK, Ill. and DREIEICH, Germany, June 21, 2011 /PRNewswire/ -- Abbott an	nigel bates	-	06/21/2011 10:38 AM

Go to reply# or date (mm/dd/yy):